Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,876,068
  • Shares Outstanding, K 89,105
  • Annual Sales, $ 256,580 K
  • Annual Income, $ -76,970 K
  • 60-Month Beta 1.58
  • Price/Sales 14.63
  • Price/Cash Flow N/A
  • Price/Book 7.86
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.32
  • Most Recent Earnings -0.89 on 05/07/20
  • Next Earnings Date 08/13/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.58
  • Number of Estimates 5
  • High Estimate 0.57
  • Low Estimate -1.07
  • Prior Year 1.26
  • Growth Rate Est. (year over year) -146.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.12 +35.43%
on 06/08/20
44.05 -1.25%
on 07/02/20
+9.58 (+28.24%)
since 06/02/20
3-Month
31.65 +37.44%
on 04/03/20
44.05 -1.25%
on 07/02/20
+9.46 (+27.79%)
since 04/02/20
52-Week
22.65 +92.05%
on 03/19/20
48.95 -11.13%
on 12/10/19
-0.88 (-1.98%)
since 07/02/19

Most Recent Stories

More News
Calidi Biotherapeutics Announces Appointment of Jim Schoeneck, Accomplished Biotech Executive, to Board of Directors

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, announced today the appointment of veteran biotech executive and...

FGEN : 43.50 (+3.25%)
KKR Acquires Stake in First Gen through Voluntary Tender Offer

Global investment firm KKR today announced that, following the completion of the voluntary tender offer period by Valorous Asia Holdings (the "Offeror"), an entity owned by KKR investment funds, the Offeror...

FGEN : 43.50 (+3.25%)
KKR : 31.20 (+1.13%)
Theravance Doses First Patient in Phase II Coronavirus Study

Theravance (TBPH) initiates dosing in a mid-stage study, evaluating its JAK inhibitor TD-0903 for the potential treatment of hospitalized patients with acute lung injury due to COVID-19.

AZN : 53.80 (+0.90%)
RHHBY : 43.7900 (-0.55%)
TBPH : 20.52 (-0.68%)
FGEN : 43.50 (+3.25%)
FibroGen Begins Phase II Study for Acute Coronavirus in US

FibroGen (FGEN) enrolls the first patient in a placebo-controlled phase II study on pamrevlumab in hospitalized patients with acute COVID-19 infection in the United States.

AZN : 53.80 (+0.90%)
RHHBY : 43.7900 (-0.55%)
AMGN : 258.24 (+1.22%)
FGEN : 43.50 (+3.25%)
Fibrogen Inc Rises 3.81% on Heavy Volume: Watch For Potential Pullback

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $42.58 to a high of $43.84. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $42.30...

FGEN : 43.50 (+3.25%)
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19

FibroGen, Inc. (NASDAQ: FGEN) today announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 Study investigating the efficacy and safety of pamrevlumab in hospitalized patients...

FGEN : 43.50 (+3.25%)
FibroGen Appoints Thane Wettig as Chief Commercial Officer

FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of Thane Wettig to the newly-created position of Chief Commercial Officer, where he will lead FibroGen's commercialization efforts, leveraging more...

FGEN : 43.50 (+3.25%)
Look for Shares of Fibrogen Inc to Potentially Pullback after Yesterday's 1.51% Rise

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $39.82 to a high of $41.15. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $40.63...

FGEN : 43.50 (+3.25%)
FibroGen (FGEN) in Focus: Stock Moves 6.5% Higher

FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

ALDX : 4.17 (unch)
FGEN : 43.50 (+3.25%)
FibroGen Initiates Phase II/III Study in Severe Coronavirus

FibroGen (FGEN) starts a phase II/III study in Italy on pamrevlumab versus standard of care in patients with severe COVID-19 infection.

AZN : 53.80 (+0.90%)
RHHBY : 43.7900 (-0.55%)
AMGN : 258.24 (+1.22%)
FGEN : 43.50 (+3.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade FGEN with:

Business Summary

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development...

See More

Key Turning Points

2nd Resistance Point 45.03
1st Resistance Point 44.26
Last Price 43.50
1st Support Level 42.52
2nd Support Level 41.55

See More

52-Week High 48.95
Last Price 43.50
Fibonacci 61.8% 38.90
Fibonacci 50% 35.80
Fibonacci 38.2% 32.70
52-Week Low 22.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar